de Azambuja E - Search Results

1

Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.

R Ferreira A, Ferreira S, Lambertini M, Maurer C, Martel S, Costa L, Ponde N, de Azambuja E. R Ferreira A, et al. Among authors: de azambuja e. Eur J Cancer. 2021 Feb;144:351-359. doi: 10.1016/j.ejca.2020.11.023. Epub 2020 Dec 31. Eur J Cancer. 2021. PMID: 33388492

2

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F. Colozza M, et al. Among authors: de azambuja e. Oncologist. 2007 Mar;12(3):253-70. doi: 10.1634/theoncologist.12-3-253. Oncologist. 2007. PMID: 17405890 Free article. Review.

3

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. de Azambuja E, et al. Among authors: de castro g jr. Br J Cancer. 2007 May 21;96(10):1504-13. doi: 10.1038/sj.bjc.6603756. Epub 2007 Apr 24. Br J Cancer. 2007. PMID: 17453008 Free PMC article.

4

Trastuzumab (herceptin) for early-stage breast cancer.

Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M. Ismael G, et al. Among authors: de azambuja e. Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. doi: 10.1016/j.hoc.2007.03.003. Hematol Oncol Clin North Am. 2007. PMID: 17512447 Review.

5

Trastuzumab for early breast cancer: current status and future directions.

Dinh P, de Azambuja E, Piccart-Gebhart MJ. Dinh P, et al. Among authors: de azambuja e. Clin Adv Hematol Oncol. 2007 Sep;5(9):707-17. Clin Adv Hematol Oncol. 2007. PMID: 17982412 Review.

6

Current perspectives of epothilones in breast cancer.

Cardoso F, de Azambuja E, Lago LD. Cardoso F, et al. Among authors: de azambuja e. Eur J Cancer. 2008 Feb;44(3):341-52. doi: 10.1016/j.ejca.2007.11.019. Eur J Cancer. 2008. PMID: 18178426 Review.

7

[The new generation of breast cancer clinical trials: the right drug for the right target].

de Azambuja E, Cardoso F, Meirsman L, Straehle C, Dolci S, Vantongelen K, Piccart-Gebhart M. de Azambuja E, et al. Bull Cancer. 2008 Mar;95(3):352-7. doi: 10.1684/bdc.2008.0587. Bull Cancer. 2008. PMID: 18390416 Review. French.

8

HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?

Widakowich C, Dinh P, de Azambuja E, Awada A, Piccart-Gebhart M. Widakowich C, et al. Among authors: de azambuja e. Anticancer Agents Med Chem. 2008 Jun;8(5):488-96. doi: 10.2174/187152008784533062. Anticancer Agents Med Chem. 2008. PMID: 18537532 Review.

9

Jumping higher: is it still possible? The ALTTO trial challenge.

Tomasello G, de Azambuja E, Dinh P, Snoj N, Piccart-Gebhart M. Tomasello G, et al. Among authors: de azambuja e. Expert Rev Anticancer Ther. 2008 Dec;8(12):1883-90. doi: 10.1586/14737140.8.12.1883. Expert Rev Anticancer Ther. 2008. PMID: 19046108 Review.

10

Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.

Bedard PL, de Azambuja E, Cardoso F. Bedard PL, et al. Among authors: de azambuja e. Curr Cancer Drug Targets. 2009 Mar;9(2):148-62. doi: 10.2174/156800909787581024. Curr Cancer Drug Targets. 2009. PMID: 19275756 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

328 results

Search Page

Filters